Professor Qiang Zhang
Chief Scientist of National "973" Key Basic Research Project
Tel: +86-10-82802791
Fax: +86-10-82802791
E-mail:zqdodo@bjmu.edu.cn
Lab Website: http://sklnbd.bjmu.edu.cn/qianglab/
Dr. Qiang Zhang received his Bachelor’s degree in Beijing Medical College in 1982 and received his Ph.D degree at West China University of Medical Sciences in 1995. After working in Sichuan Industrial Institute of Antibiotics for 10 years, in 1995 he moved to School of Pharm. Sci., Peking University where he was promoted to Associated Professor in 1996 and Professor in 1999. He began his study in nanomedicine in 1992 when reading for Ph.D degree. Now more than 300 SCI papers were published, which was highly cited, garnered numerous awards, and boosted related pharmaceutics research. As the DDS people, he have developed serial DDS into market and some others into clinical study. One of them has become the star product of a major domestic pharmaceutical company, having brought in significant economic and social benefits.
Currently he is the Honor Chair of Pharmaceutics Committee of Chinese Pharmaceutical Association (CPA), Founder and Vice-Chair of Nanomedicines Committee of CPA, Vice-Chair of Pharmaceutics Committee of Chinese Pharmacopoeia, Expert for Center of Drug Evaluation of CFDA, the first Editorial board member of J Controlled Release in China, and so on. He was also the first President of CRS-China Chapter and the Vice-Dean of School of Pharm. Sci., Peking University.
Research Interests:
Molecular Pharmaceutics and the translational study on novel DDS, including the mechanism and translational studies on novel drug delivery systems for water-insoluble drugs, antitumor drugs and biotechnology drugs.
Representative Publications
1. Wang, Xiaoyou; Zhang Qiang, et al. Anisotropy in Shape and Ligand-Conjugation of Hybrid Nanoparticulates Manipulates the Mode of Bio-Nano Interaction and Its Outcome. Advanced Functional Materials. 2017, 27 (31)
2. Dai, Wenbing; Zhang Qiang, et al. Combination antitumor therapy with targeted dual-nanomedicines. Advanced Drug Delivery Reviews. 2017, 115: 23-45
3. Liang, Yanqin; Zhang Qiang, et al. A Nanosystem of Amphiphilic Oligopeptide- Drug Conjugate Actualizing Both alpha v beta 3 Targeting and Reduction-Triggered Release for Maytansinoid. Theranostics. 2017,7(13): 3306-3318
4. Gao Wei; Zhang Qiang, et al. The use of electronic-neutral penetrating peptides cyclosporin A to deliver pro-apoptotic peptide: A possibly better choice than positively charged TAT. Journal of Controlled Release. 2017, 261: 174-186
5. Li, Suxin; Zhang Qiang, et al. Novel Biological Functions of ZIF-NP as a Delivery Vehicle: High Pulmonary Accumulation, Favorable Biocompatibility, and Improved Therapeutic Outcome. Advanced Functional Materials. 2016, 26(16): 2715-2727
6. Wang, Dan; Zhang Qiang, et al. The modulation of tumor vessel permeability by thalidomide and its impacts on different types of targeted drug delivery systems in a sarcoma mouse model. Journal of Controlled Release. 2016, 238: 186-196
7. Fu JJ, Zhang Q, et al. Macrophage mediated biomimetic delivery system for the treatment of lung metastasis of breast cancer, Journal of Controlled Release, 2015,204:11-19
8. Hu Hongxiang, Zhang Hua, Zhang Qiang, et al. A novel localized co-delivery system with lapatinib microparticles and paclitaxel nanoparticles in a peritumorally injectable in situ hydrogel. Journal of Controlled Release, 2015,220:189-200
9. Guo Z, Zhang Q, et al. Targeting efficiency of RGD-modified nanocarriers with different ligand intervals in response to integrin αvβ3 clustering. Biomaterials. 2014 Jul; 35(23):6106-17.
10. Qin C, Zhang Q, et al. The impact of a chlorotoxin-modified liposome system on receptor MMP-2 and the receptor-associated protein ClC-3. Biomaterials. 2014 Jul;35(22):5908-20.
